PMID- 36120053
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220920
IS  - 2470-1343 (Electronic)
IS  - 2470-1343 (Linking)
VI  - 7
IP  - 36
DP  - 2022 Sep 13
TI  - Programmable Drug Release from a Dual-Stimuli Responsive Magnetic Metal-Organic 
      Framework.
PG  - 32588-32598
LID - 10.1021/acsomega.2c04144 [doi]
AB  - Along with the increasing incidence of cancer and drawbacks of traditional drug 
      delivery systems (DDSs), developing novel nanocarriers for sustained 
      targeted-drug release has become urgent. In this regard, metal-organic frameworks 
      (MOFs) have emerged as potential candidates due to their structural flexibility, 
      defined porosity, lower toxicity, and biodegradability. Herein, a FeMn-based 
      ferromagnetic MOF was synthesized from a preassembled Fe(2)Mn(mu(3)-O) cluster. 
      The introduction of the Mn provided the ferromagnetic character to FeMn-MIL-88B. 
      5-Fluoruracil (5-FU) was encapsulated as a model drug in the MOFs, and its pH and 
      H(2)S dual-stimuli responsive controlled release was realized. FeMn-MIL-88B 
      presented a higher 5-FU loading capacity of 43.8 wt % and rapid drug release 
      behavior in a tumor microenvironment (TME) simulated medium. The carriers can 
      rapidly release loaded drug of 70% and 26% in PBS solution (pH = 5.4) and NaHS 
      solution (500 muM) within 24 h. The application of mathematical release models 
      indicated 5-FU release from carriers can be precisely fitted to the first-order, 
      second-order, and Higuchi models of release. Moreover, the cytotoxicity profile 
      of the carrier against human embryonic kidney cells (HEK293T) suggests no adverse 
      effects up to 100 mug/mL. The lesser toxic effect on cell viability can be 
      attributed to the low toxicity values [LD(50) (Fe) = 30 g.kg(-1), (Mn) = 1.5 
      g.kg(-1), and (terephthalic acid) = 5 g.kg(-1)] of the MOFs structural 
      components. Together with dual-stimuli responsiveness, ferromagnetic nature, and 
      low toxicity, FeMn-MIL-88B MOFs can emerge as promising carriers for drug 
      delivery applications.
CI  - (c) 2022 The Authors. Published by American Chemical Society.
FAU - Akbar, Muhammad Usman
AU  - Akbar MU
AD  - Gomal Center of Biochemistry and Biotechnology, Gomal University, Dera Ismail 
      Khan, KPK 29050, Pakistan.
AD  - Department of Chemistry and Chemical Engineering, Syed Babar Ali School of 
      Science and Engineering, Lahore University of Management Sciences (LUMS), Lahore 
      54792, Pakistan.
FAU - Badar, Muhammad
AU  - Badar M
AD  - Gomal Center of Biochemistry and Biotechnology, Gomal University, Dera Ismail 
      Khan, KPK 29050, Pakistan.
FAU - Zaheer, Muhammad
AU  - Zaheer M
AUID- ORCID: 0000-0003-2389-4396
AD  - Department of Chemistry and Chemical Engineering, Syed Babar Ali School of 
      Science and Engineering, Lahore University of Management Sciences (LUMS), Lahore 
      54792, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20220830
PL  - United States
TA  - ACS Omega
JT  - ACS omega
JID - 101691658
PMC - PMC9475617
COIS- The authors declare no competing financial interest.
EDAT- 2022/09/20 06:00
MHDA- 2022/09/20 06:01
PMCR- 2022/08/30
CRDT- 2022/09/19 04:35
PHST- 2022/07/04 00:00 [received]
PHST- 2022/08/12 00:00 [accepted]
PHST- 2022/09/19 04:35 [entrez]
PHST- 2022/09/20 06:00 [pubmed]
PHST- 2022/09/20 06:01 [medline]
PHST- 2022/08/30 00:00 [pmc-release]
AID - 10.1021/acsomega.2c04144 [doi]
PST - epublish
SO  - ACS Omega. 2022 Aug 30;7(36):32588-32598. doi: 10.1021/acsomega.2c04144. 
      eCollection 2022 Sep 13.